Wire · opportunities
FDA approves Teva's Degevma, a Xgeva biosimilar for bone-related cancer complications
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
The FDA has approved Degevma, a biosimilar to Xgeva, for preventing bone-related complications in adults and adolescents with advanced cancer, giant cell tumor of bone, and hypercalcemia of malignancy. This approval complements Teva's Ponlimsi biosimilar to Prolia, expanding their denosumab portfolio for oncology and osteoporosis, with significant potential cost savings and market impact expected in the U.S.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
The biosimilar approval market in oncology has a new lever with Teva's Degevma adding competitive pressure on originator pricing. You can approach payers now with alternatives in bone complication therapies and capture budget-sensitive demand before interchangeability rules complicate uptake.
◆ Coverage
2 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics